Scynexis (SCYX) Cost of Revenue (2013 - 2023)
Scynexis' (SCYX) quarterly Cost of Revenue came in at $14.7 million in Q4 2023, up 7391.84% on a YoY basis from $196000.0 in Q4 2022, and up 3774.41% quarter-over-quarter from $379000.0 in Q3 2023.
Analysis
Scynexis (SCYX) Cost of Revenue (2013 - 2023) Analysis & Trends
Scynexis (SCYX) has reported Cost of Revenue for 6 consecutive years, with $14.7 million the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Cost of Revenue rose 7391.84% year-over-year to $14.7 million; the trailing twelve-month figure through Sep 2024 stood at $14.7 million (up 1190.33% YoY), and the FY2023 full-year result was $15.6 million, up 2387.9% from the prior year.
- Cost of Revenue rose to $14.7 million in Q4 2023 per SCYX's latest filing, from $379000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $14.7 million in Q4 2023 and bottomed at $99000.0 in Q1 2022.
- Historically, Cost of Revenue has averaged $1.7 million across 3 years, with a median of $178000.0 in 2021.
- The sharpest annual moves came in 2022 and 2023: Cost of Revenue climbed 17.37% in 2022, then soared 7391.84% in 2023.
- Over 3 years, Cost of Revenue stood at $167000.0 in 2021, then increased by 17.37% to $196000.0 in 2022, then jumped by 7391.84% to $14.7 million in 2023.
- According to Business Quant data, Cost of Revenue over the past three periods registered $14.7 million, $379000.0, and $426000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.81 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.58 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 489.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 360.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 145.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 93.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 776.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 284,000.00 |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 14.68 Mn |
| Sep 30, 2023 | 379,000.00 |
| Jun 30, 2023 | 426,000.00 |
| Mar 31, 2023 | 137,000.00 |
| Dec 31, 2022 | 196,000.00 |
| Sep 30, 2022 | 189,000.00 |
| Jun 30, 2022 | 144,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Dec 31, 2021 | 167,000.00 |
| Sep 30, 2021 | 145,000.00 |
| Mar 31, 2015 | 3.23 Mn |
| Dec 31, 2014 | 3.65 Mn |
| Sep 30, 2014 | 3.66 Mn |
| Jun 30, 2014 | 4.18 Mn |
| Mar 31, 2014 | 3.96 Mn |
| Dec 31, 2013 | 3.77 Mn |
| Sep 30, 2013 | 3.99 Mn |
| Jun 30, 2013 | 4.40 Mn |
| Mar 31, 2013 | 4.15 Mn |